Sage Journals: Discover world-class research

Abstract

Background

Psoriasis is nowadays regarded as a systemic inflammatory disorder. Among the topicals, vitamin D derivates are often applied on the skin for their anti-inflammatory and immune-modulatory properties. Vitamin D serum levels in psoriasis (PsO) patients are still debated and an eventual depletion may offer the rational to integrate anti-psoriatic therapies with oral vitamin D. Then, we aimed to perform a systematic review and meta-analysis on the current evidence towards serum vitamin D level in PsO.

Methods

We searched in PubMed, Scopus, Web of Sciences, ScienceDirect and Science Information Database (SID) using the terms “Vitamin D” and “Psoriasis” including manuscripts in English, Italian and Persian. Duplications were excluded using EndNote software and records were screened by title, abstract and full-text. Quality assessment of studies was assessed using Newcastle Ottawa Checklist (NOS). Psoriasis odds ratio (OR) and mean serum vitamin D levels were calculated and displayed in Forest-plots. Heterogeneity indexes were evaluated using I² and Q. Sensitivity analysis and publication biases were also considered.

Results

From 3006 records extracted, after removing duplicates and analyzing full texts we finally included 19 manuscripts involving a total of 1387 PsO cases and 6939 controls. PsO patients exhibited a substantial odds ratio (3.07, 95% CI: 1.56-6.04) for lower serum vitamin D levels compared to the control group. Standardized Mean Difference (SMD) of vitamin D in PsO versus controls was −0.92 (−1.33 to −0.51).

Conclusion

Psoriatic patients displayed higher risk to have a vitamin D deficiency. Interventional studies to verify the preventive value are mandatory.

Keywords

psoriasis serum vitamin D protective factor meta-analysis

Introduction

Psoriasis (PsO) is currently regarded as a systemic inflammatory disorder^1‐3 with a great comorbidity burden, ranging from cardiovascular to respiratory diseases.^4‐6 Prevalence of psoriasis in general population has been estimated 2–3% with significant variability among ethnicities.^7,8 Although PsO pathogenesis is still debated, the evidence of susceptible genes,⁹ the identified triggers¹⁰ and nutritional data^11,12 seem to suggest a multifactorial pathogenesis between a susceptible genetic asset is triggered by a predisposing environment.²

Topicals containing vitamin D derivates are widely used as single or combined therapy in mild PsO, and sometimes also in moderate to severe patients during systemic anti-psoriatic therapies.¹

Vitamin D deficiency is a common finding worldwide, especially in patients affected by autoimmune disorders.^13,14 Beside race and congenital vitamin D metabolic problems, the other factors conditioning serum vitamin D levels are modifiable including insufficient sunlight exposure, intestinal malabsorption and insufficient intake.^13‐15 Since vitamin D also modulates immunity, both innate and adaptive, its deficiency may trigger or inefficiently counteracts systemic inflammation.¹⁶ Furthermore, low vitamin D levels were described cardiovascular and metabolic disorders, malignancies and several autoimmune (ie systemic lupus erythematous and rheumatoid arthritis) and inflammatory (ie inflammatory bowel disease and psoriasis) diseases.¹⁷

Vitamin D supplementation was studied in several dermatological diseases, such as psoriasis, characterized by low vitamin D serum levels, without any objective improvement.⁷ However, low levels of vitamin D are commonly regarded as a detrimental parameter to correct with supplementation. Despite the association between vitamin D low level and PsO-related aspects is still debated, low levels of vitamin D is notoriously related with osteoporosis and at the same time also psoriasis is related to osteoporosis.¹⁸

In 2019 a meta-analysis have been done, studying association between vitamin D level and psoriasis combining results of 10 primary study (pooled mean difference: −6.13 ng/ml).¹⁹ Further investigation in databases showed there were more records and primary studies investigating this association, so a new meta-analysis is essential in order to update the results. In the study by Pitukweerakul et al,¹⁹ Mean Difference (MD) have been reported instead of Standardized Mean Difference (SMD) although they have mentioned that SMD have been calculated in methods section.

Since several studies assessed vitamin D serum levels in PsO patients with discordant results,^3,15,20‐31 we aimed to analyze the current evidence in order to legitimate dermatologists to methodically test every PsO patient.

Materials and Methods

This study was designed based on Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) and the protocol has been registered in PROSPERO registration number “CRD42018100192”.³²

Inclusion and Exclusion Criteria

Inclusion and exclusion criteria were structured with PICO. We included every observational study that report serum vitamin D levels in psoriatic patients and controls. Vitamin D levels below 20 UI were considered as deficiency.³³ Every study present in the assessed databases from the beginning until January 19th 2020 in English and Persian were included.

Search Strategy

Databases including PubMed, Scopus, ScienceDirect, Web of Science and Google Scholar search engine were searched with designated MeSH terms and OR, AND, NOT operators. Persian database SID was searched using Persian keywords for “Vitamin D” and “Psoriasis”. Search strategy was as follows:

(“Vitamin D” OR “Cholecalciferol” OR “25-Hydroxyvitamin D” OR “25-OH vitamin D” OR “25-(OH) D” OR “25-hydroxy Vitamin D”) AND (“Psoriasis” OR “Pustulosis of Palms and Soles” OR “Pustulosis Palmaris et Plantaris” OR “Palmoplantar Pustulosis” OR “Pustular Psoriasis of Palms and Soles”)

We carefully also evaluated references in the included studies to improve the sensitivity of our searching phase. EndNote X9 was used to manage the studies.

Study Selection

We preliminary deleted duplicates, then we have screened studies by title and abstract to exclude unrelated records. Selected full-texts were carefully evaluated to verify inclusion and exclusion criteria. This process was performed by two authors and in case of disagreement the study was discussed with the third author that made the final decision.

Data Extraction

Data extraction was performed independently by two authors. From each included study we extracted: first author name, study title, journal title, publication year, study country, article language, numerosity of PsO patients and controls, mean and standard deviation of vitamin D level, number of individuals with vitamin D level <20 UI and ≥ 20 UI, serum vitamin D level measurement unit, pool of patients and selection methods, cases-controls matching criteria, patients’ age and gender.

Risk of Bias Assessment

Risk of bias was assessed using Newcastle-Ottawa Scale (NOS) checklist.³⁴ This checklist includes three sections, namely Selection, Comparability and Exposure, and globally score studies from 0 to 9 points. Studies that obtained a score < 5 points were excluded. Selection criteria maximum score is 4, Comparability is 2 and Exposure is 3. Assessment was done independently by two people.

Statistical Analysis

Data were analyzed using STATA, version11. Heterogeneity index was performed with Cochran (Q) and I² tests. Odds ratios and 95% confidence intervals were performed using Metan command, random effect model and reverse variance. To evaluate standardized difference in vitamin D mean serum levels in cases and controls, Metan command, random effect model and reverse variance method and Cohen's d were used. Forest plot was used to graphically represent the estimate standardized difference in the mean serum vitamin D with 95% confidence interval. Sensitivity analysis was performed to evaluate the weight of each study in the overall meta-analysis. Funnel diagram and Egger test were used to investigate publication bias. The potential presence of publication bias was evaluated with Trim and fill analysis.

Results

The preliminary search results in 3006 records that after removing duplicates 1719 remained. Then, after title and abstract screening phase 1698 were excluded and only 21 articles were further screened with the full text. Finally, only 19 papers^{2,3,15,16,20‐26,28,30,31,35‐39} met the inclusion criteria (Figure 1).

Figure 1.

Study selection using PRISMA flow diagram.

Table 1 displays the characteristics of the included primary studies published between 1990 to 2018. Twenty six percent of the studied were published in 2018. Interestingly two studies included only male subjects.^28,38 In the great majority of the included studies the matching criteria were age and gender. Characteristics of included studies are summarized in details in Table 1.

Table 1.

Characteristics of Primary Studies Included to the Present Meta-Analysis.

First author	Year	Country	Gender	Matching Criteria	Case			Control			Case		Control		Quality score*
First author	Year	Country	Gender	Matching Criteria	Sample size	Mean	SD	Sample size	Mean	SD	No. vitamin D < 20	No. vitamin D ≥ 20	No. vitamin D < 20	No. vitamin D ≥ 20	Quality score*
Morimoto²⁴	1990	Japan	Male/Female	Age	34	22	7	24	21	15	-	-	-	-	6
Gisondi²²	2012	Italy	Male/Female	-	145	20.7	11.3	141	37.1	27.6	81	64	42	99	7
Orgaz-Molina²⁵	2012	Spain	Male/Female	Age, Gender	43	24.41	7.8	43	29.53	9.38	11	32	4	39	6
Atwa ²¹	2013	Saudi Arabia	Male/Female	-	43	11.74	3.6	40	24.55	11.21	43	0	16	24	7
Al-Mutairi ²⁰	2013	Kuwait	Male/Female	Age, Gender	100	11.83	3.75	100	21.43	7.85	99	1	65	35	5
Zaher ³⁹	2013	Egypt	Male/Female	Age, Gender, Skin Phototype	48	21.05	3.66	40	37.02	5.06	12	36	0	40	6
Wilson ³¹	2013	USA	Male/Female	Age, Gender, Race/Ethnicity	148	24.2	8.75	5693	23.6	26.7	49	99	1987	3706	6
Orgaz-Molina ²⁶	2014	Spain	Male/Female	Age, Gender	46	30.52	9.29	46	38.31	9.56	9	37	0	46	7
Petho ²⁸	2015	Hungary	Male	Age	53	-	-	53	-	-	27	26	15	38	8
Zuchi ³	2015	Brazil	Male/Female	-	20	23.55	7.6	20	22.35	3.1	5	15	4	16	3
Chandrashekar ³⁵	2015	South India	Male/Female	Age, Gender	43	13.3	6.9	43	22.4	18.4	-	-	-	-	6
Solak ³⁰	2016	Turkey	Male/Female	-	43	8.49	3.48	41	10.09	5.64	-	-	-	-	7
Darjani ³⁶	2016	Iran	Male/Female	Age, Gender, Skin Color	30	25.81	12.68	30	23.72	8.93	11	19	13	17	7
Maleki ²³	2016	Iran	Male/Female	Age, Gender	50	14.92	6.31	43	12.52	4.54	42	8	40	3	8
Filoni ¹⁵	2018	Italy	Male/Female	-	170	21.8	12.3	340	34.3	13.3	-	-	-	-	6
Nayak ²	2018	India	Male/Female	Age, Gender	61	18.41	9.41	61	17.24	13.03	39	22	41	20	7
Amon ¹⁶	2018	England	Male/Female	Not Matched Socioeconomically	180	22.6	10.7	71	44.1	10.7	79	101	1	70	7
Khalil ³⁷	2018	Iraq	Male/Female	Age, Gender, BMI	45	12.15	2.75	45	34.23	8.4	-	-	-	-	7
Pietrzak ³⁸	2018	Poland	Male	-	85	12	5	65	22	9	-	-	-	-	6

*Quality of studies were assessed using Newcastle-Ottawa Scale Checklist

In our meta-analysis 1387 PsO and 6939 controls from the 19 studies were included. Remarkably, from 13 studies reported vitamin D serum levels, we extracted the odd ratios in psoriatic patients versus controls, maintaining the vitamin D cut-off level of 20 UI (Figure 2).

Figure 2.

Point odds ratio and 95% confidence interval for each primary study included and overall estimation.

Studies heterogeneity were high in the 19 considered studies (I-squared = 82.2, Q = 67.25, P < 0.001). In 13 studies comparing PsO patients Vs controls, pooled odd ratio was 3.07 (95% CI, 1.56-6.04, p < 0.001) (Figure 2).

Sensitivity analysis is displayed in Figure 3 and Table 2. Funnel plot (Figure 4) showed the presence of publication biases, as well as Egger test (β=2.32, P = 0.028).

Figure 3.

Sensitivity analysis in order to investigate effect of each primary study on overall odds ratio estimate.

Figure 4.

Funnel plot describing publication bias.

Table 2.

Estimated Odds Ratio of Psoriasis Based on Vitamin D < 20 Against Vitamin D ≥ 20 After Eliminating Each One of Studies (Sensitivity Analysis).

Study omitted	Estimate	[95% Confidence Interval]
Study omitted	Estimate	Lower	Upper
Atwa (2013) ²¹	2.5677474	1.3350499	4.9386373
Gisondi (2012) ²²	3.2755024	1.5046175	7.130661
Orgaz-Molina (2012) ²⁵	3.0851779	1.499746	6.3466234
Orgaz-Molina (2014) ²⁶	2.8107436	1.4208449	5.5602694
Petho (2015) ²⁸	3.2324226	1.5303581	6.8275232
Solak (2016) ³⁰	3.0694969	1.5586636	6.0448008
Dorjani (2016) ³⁶	3.6065519	1.7409427	7.471364
Filoni (2018) ¹⁵	3.0694969	1.5586636	6.0448008
Maleki (2016) ²³	3.6544411	1.8073723	7.3891468
Zuchi (2015) ³	3.3383543	1.6254582	6.856288
Al-Mutairi (2013) ²⁰	2.4635639	1.2867666	4.7165875
Nayak (2018) ²	3.6746533	1.7368428	7.7744961
Chandrashekar (2015) ³⁵	3.0694969	1.5586636	6.0448008
Zaher (2013) ³⁹	2.7858202	1.4112042	5.499413
Wilson (2013) ³¹	3.7627478	1.7398312	8.1377258
Morimoto (1990) ²⁴	3.0694969	1.5586636	6.0448008
Amon (2018) ¹⁶	2.4511313	1.2825447	4.6844716
Khalil (2018) ³⁷	3.0694969	1.5586636	6.0448008
Pietrzak (2018) ³⁸	3.0694969	1.5586636	6.0448008
Combined	3.0694968	1.5586636	6.0448008

Trim and fill test estimated 3 possible missing studies (Figure 5). Considering this fact, odds ratio became 1.40 (CI 95% 1.12-1.76) using fixed effect model and 1.76 (CI 95% 0.86-3.59) using random effect model.

Figure 5.

Filled funnel plot of psoriasis odds ratio.

In 19 studies mean and standard deviation of serum vitamin D level in case and control group were reported. Combining the results of 19 primary studies, pooled SMD of serum vitamin D level estimated −0.92 (−1.33, −0.51) (Figure 6). Heterogeneity was high (I-squared = 96%, Q = 421.46, P < 0.001) but based on Egger test results publication bias for estimating SMD was not statistically significant (β=1.25, P = 0.197).

Figure 6.

Standardized mean difference (SMD) of serum vitamin D level in patients with psoriasis in compare with control group.

Discussion

In this meta-analysis the association between psoriasis and vitamin D have been investigated. Low vitamin D (<20 UI) was significantly associated with psoriasis. Standardized mean vitamin D level was significantly lower in psoriatic patients than healthy controls.

Vitamin D is a crucial nutrient synthesized in the skin through exposure to ultraviolet B (UVB) sunlight, leading to the conversion of 7-dehydrocholesterol to pre-vitamin D3 and further to vitamin D3.⁴⁰ Measurement of vitamin D status involves assessing various markers and metabolites. One of the most widely used markers is the circulating concentration of 25-hydroxyvitamin D (25(OH)D). This marker is favored due to its relatively long half-life, stability, and reflection of both endogenous synthesis and dietary intake of vitamin D. Serum 25(OH)D concentration provides a reliable indicator of an individual's overall vitamin D status, allowing healthcare professionals to classify individuals as deficient, insufficient, or sufficient.³³ This approach aids in determining appropriate supplementation and intervention strategies to maintain optimal vitamin D levels and prevent associated health risks.^33,40,41 Vitamin D also plays a pivotal role is skin homeostasis, in fact it is involved in antimicrobial peptides synthesis and regulation.⁴² Vitamin D also showed immunomodulatory effects exerted on Langerhans cells, preventing activated T-cell proliferation.^43,44 Its pleiotropic effect affects both plasmacytoid dendritic cells (pDC)⁴⁵ Th-17 ones, two abundant cytotypes in psoriatic active lesions.⁴⁶

Interventional trials that assessed vitamin D oral integration in psoriatic patients are controversial. Disphanurat et al administered 60,000 IU of vitamin D2 twice weeks for 6 months in a cohort of psoriatic patients obtaining a significant PASI reduction without adverse events.⁴⁷ Conversely, Ingram et al did not appreciate a severity improvement after 100,000 IU vitamin D3 supplementation for 12 month.⁴⁸

Previous meta-analysis on vitamin D and psoriasis severity by Pitukweerakul et al¹⁹ have estimated pooled MD of vitamin D, −6.13 (CI 95% −10.93, −1.32). Since we have used SMD instead of MD the pooled estimate is smaller. However, Pitukweerakul et al¹⁹ have missed number of studies. They have also did not report pooled OR for psoriasis and vitamin D deficiency.

Despite our meta-analysis shed light on the association existing between vitamin D deficiency and psoriasis, we are far to plenty understand the temporal association. Furthermore, future studies should focus on the potential relationship between vitamin D levels and PsO severity. One approach could involve longitudinal cohort studies that track individuals over time to better establish whether vitamin D deficiency precedes the onset of psoriasis or if psoriasis contributes to lower vitamin D levels. Additionally, examining the molecular mechanisms underlying this relationship could provide insights into the causal direction.

Our meta-analysis focused on the difference in vitamin D levels in psoriatic patients compared to controls, but did not account for the constellation of well-known factors that influence vitamin D serum levels. In literature, vitamin D serum levels recognized as modulators several factors, included air pollution, drugs, vaccination, infection, lifestyle, obesity, sun exposure, dyslipidemia, mental stress, hypertension, diabetes and psoriasis family history.⁴⁹ Ultraviolet radiation has been shown to be linked with improvement in psoriasis by increasing Vitamin D and immunomodulatory effects.⁵⁰ Vitamin D also plays a crucial role in modulating the interaction between the innate and adaptive immune systems, contributing to a reduction in autoimmune disease activity and reducing the psoriasis flares in these patients.⁵¹

Thus, we suggest that PsO patients with such a risk factor should be mandatory tested in order to potentially be supplemented with vitamin D. Despite the numerous uncertainties on the effect of oral vitamin D supplementation in psoriasis, an interventional approach should be encouraged to prevent osteoporosis in these patients.

Publication biases and language inclusion criterium may have limited the studies evaluated, however we statistically account for these aspects. The main limitation of any meta-analysis remains the primary studies quality. In several included studies extracting data based on gender and age group was not possible.

Conclusion

This meta-analysis showed that odds of vitamin D deficiency is higher in psoriatic patients than control. Critically evaluating the current literature remains unclear if the vitamin D deficiency is present before psoriasis development or the psoriasis causes itself vitamin D deficiency. Hence, we recommend checking vitamin D serum levels in psoriatic patients and supplement them in case of low levels.

Footnotes

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Author Contributions

M.M has contributed in study design, analysis and data interpretation. G.D has contributed in data interpretation, writing and editing manuscript. M.K, M.Kh and F.N have contributed to data collection, analysis and interpretation. A.H has contributed in writing manuscript, data interpretation, writing and editing manuscript.

ORCID iD

Amirhossein Hessami

References

Bergler-Czop

Brzezińska-Wcisło

. Serum vitamin D level–the effect on the clinical course of psoriasis. Adv Dermatol Allergol/Postȩpy Dermatologii i Alergologii. 2016;33(6):445. doi:10.5114/ada.2016.63883

Nayak

Girisha

Noronha

Sripathi

. Low vitamin D in psoriasis: Reality or myth? Indian J Dermatol. 2018;63(3):255.

Zuchi

Azevedo

Tanaka

Schmitt

Martins

LEAM

. Serum levels of 25-hydroxy vitamin D in psoriatic patients. An Bras Dermatol. 2015;90(3):430‐432.

Conic

Damiani

Schrom

, et al. Psoriasis and psoriatic arthritis cardiovascular disease endotypes identified by red blood cell distribution width and mean platelet volume. J Clin Med. 2020;9(1):186.

Santus

Rizzi

Radovanovic

, et al. Psoriasis and respiratory comorbidities: the added value of fraction of exhaled nitric oxide as a new method to detect, evaluate, and monitor psoriatic systemic involvement and therapeutic efficacy. BioMed Res Int. 2018;2018:3140682. doi:10.1155/2018/3140682

Seth

Ehlert

Golden

, et al. Interaction of resistin and systolic blood pressure in psoriasis severity. J Invest Dermatol. 2020;140(6):1279-1282.E1. doi:10.1016/j.jid.2019.07.727

Barrea

Savanelli

Di Somma

, et al. Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. Rev Endocr Metab Disord. 2017;18(2):195‐205.

Karimkhani

Dellavalle

Karimi

, et al. Burden of skin and subcutaneous diseases in Iran and neighboring countries: Results from the global burden of disease study 2015. Arch Iran Med. 2017;20(7):429‐440.

Capon

. The genetic basis of psoriasis. Int J Mol Sci. 2017;18(12):2526.

10.

Tsai

Y-C

Tsai

T-F

. A review of antibiotics and psoriasis: Induction, exacerbation, and amelioration. Expert Rev Clin Pharmacol. 2019;12(10):981‐989.

11.

Damiani

Watad

Bridgewood

, et al. The impact of ramadan fasting on the reduction of PASI score, in moderate-to-severe psoriatic patients: A real-life multicenter study. Nutrients. 2019;11(2):277.

12.

Kocic

Damiani

Stamenkovic

, et al. Dietary compounds as potential modulators of microRNA expression in psoriasis. Ther Adv Chronic Dis. 2019;10. doi:10.1177/2040622319864805

13.

Al-Dhubaibi

. Association between vitamin D deficiency and psoriasis: An exploratory study. Int J Health Sci. 2018;12(1):33.

14.

Holick

Chen

. Vitamin D deficiency: A worldwide problem with health consequences. Am J Clin Nutr. 2008;87(4):1080S‐1086S.

15.

Filoni

Vestita

Congedo

Giudice

Tafuri

Bonamonte

. Association between psoriasis and vitamin D: duration of disease correlates with decreased vitamin D serum levels: An observational case-control study. Medicine. 2018;97(25):e11185. doi:10.1097/MD.0000000000011185

16.

Amon

Baier

Yaguboglu

Ennis

Holick

Amon

. Serum 25-hydroxyvitamin D levels in patients with skin diseases including psoriasis, infections, and atopic dermatitis. Dermatoendocrinol. 2018;10(1):e1442159.

17.

Hambly

Kirby

. The relevance of serum vitamin D in psoriasis: A review. Arch Dermatol Res. 2017;309(7):499‐517.

18.

Muñoz-Torres

Aguado

Daudén

Carrascosa

Rivera

. Osteoporosis y psoriasis. Actas Dermosifiliogr. 2019;110(8):642‐652.

19.

Pitukweerakul

Thavaraputta

Prachuapthunyachart

Karnchanasorn

. Hypovitaminosis D is associated with psoriasis: A systematic review and meta-analysis. Kans J Med. 2019;12(4):103‐108.

20.

Al-Mutairi

Eassa

Nair

. Measurement of vitamin D and cathelicidin (LL-37) levels in patients of psoriasis with co-morbidities. Indian J Dermatol Venereol Leprol. 2013;79(4):492.

21.

Atwa

Balata

Hussein

Abdelrahman

Elminshawy

. Serum 25-hydroxyvitamin D concentration in patients with psoriasis and rheumatoid arthritis and its association with disease activity and serum tumor necrosis factor-alpha. Saudi Med J. 2013;34(8):806‐813.

22.

Gisondi

Rossini

Di Cesare

, et al. Vitamin D status in patients with chronic plaque psoriasis. Br J Dermatol. 2012;166(3):505‐510.

23.

Maleki

Nahidi

Azizahari

Meibodi

Hadianfar

. Serum 25-OH vitamin D level in psoriatic patients and comparison with control subjects. J Cutan Med Surg. 2016;20(3):207‐210.

24.

Morimoto

Yoshikawa

Fukuo

, et al. Inverse relation between severity of psoriasis and serum 1, 25-dihydroxyvitamin D level. J Dermatol Sci. 1990;1(4):277‐282.

25.

Orgaz-Molina

Buendía-Eisman

Arrabal-Polo

Ruiz

Arias-Santiago

. Deficiency of serum concentration of 25-hydroxyvitamin D in psoriatic patients: A case-control study. J Am Acad Dermatol. 2012;67(5):931‐938.

26.

Orgaz-Molina

Magro-Checa

A-P

, et al. Association of 25-hydroxyvitamin D with metabolic syndrome in patients with psoriasis: A case-control study. Acta Derm-Venereol. 2014;94(2):142‐145.

27.

Orgaz-Molina

Magro-Checa

Rosales-Alexander

, et al. Association of 25-hydroxyvitamin D serum levels and metabolic parameters in psoriatic patients with and without arthritis. J Am Acad Dermatol. 2013;69(6):938‐946.

28.

Petho

Kulcsar-Jakab

Kalina

, et al. Vitamin D status in men with psoriatic arthritis: A case-control study. Osteoporos Int. 2015;26(7):1965‐1970.

29.

Sağ

Tekeoğlu

, et al. Comparison of 25-hidroksi vitamin D serum concentrations in patients with psoriasis and psoriatic arthritis. J Back Musculoskelet Rehabil. 2018;31(1):37‐43.

30.

Solak

Dikicier

Celik

Erdem

. Bone mineral density, 25-OH vitamin D and inflammation in patients with psoriasis. Photodermatol Photoimmunol Photomed. 2016;32(3):153‐160.

31.

Wilson

. Serum 25-hydroxyvitamin D status in individuals with psoriasis in the general population. Endocrine. 2013;44(2):537‐539.

32.

Moosazadeh

. Comparing the 25-Hydroxy vitamin D between patients with psoriasis and healthy individuals, a systematic review and meta-analysis. PROSPERO. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018100192

33.

Holick

. Vitamin D deficiency. N Engl J Med. 2007;357(3):266‐281. doi:10.1056/NEJMra070553

34.

Stang

. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603‐605.

35.

Chandrashekar

Kumari

Rajappa

Revathy

Munisamy

Thappa

. 25-hydroxy vitamin D and ischaemia-modified albumin levels in psoriasis and their association with disease severity. Br J Biomed Sci. 2015;72(2):56‐60.

36.

Darjani

Mehdi Zadeh

Alizadeh

, et al. Comparison of serum vit D level between psoriasis patients and normal population. Alborz Univ Med J. 2016;5(4):223–228. doi:10.18869/acadpub.aums.5.4.223

37.

Khali

A-H

Abd

Alta'ee

Al-Sultany

Al-Hattab

. Vitamin D 3 level and its receptor of patients with psoriasis: A case control study. Euromediterranean Biomed J. 2018;13(34):150–154. doi:0.3269/1970-5492.2018.13.34

38.

Pietrzak

Grywalska

, et al. Serum concentrations of interleukin 18 and 25-hydroxyvitamin D3 correlate with depression severity in men with psoriasis. PloS One. 2018;13(8):e0201589. doi:10.1371/journal.pone.0201589

39.

Zaher

HAE-M

El-Komy

MHM

Hegazy

El Khashab

HAM

Ahmed

. Assessment of interleukin-17 and vitamin D serum levels in psoriatic patients. J Am Acad Dermatol. 2013;69(5):840‐842. doi:10.1016/j.jaad.2013.07.026

40.

Bikle

. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol. Mar 20 2014;21(3):319‐329. doi:10.1016/j.chembiol.2013.12.016

41.

Cashman

Dowling

Škrabáková

, et al.

Vitamin D deficiency in Europe: Pandemic?

Am J Clin Nutr. Apr 2016;103(4):1033‐1044. doi:10.3945/ajcn.115.120873

42.

Umar

Sastry

Al Ali

Al-Khulaifi

Wang

Chouchane

. Vitamin D and the pathophysiology of inflammatory skin diseases. Skin Pharmacol Physiol. 2018;31(2):74‐86. doi:10.1159/000485132

43.

Bagot

Charue

Lescs

Pamphile

Revuz

. Immunosuppressive effects of 1,25-dihydroxyvitamin D3 and its analogue calcipotriol on epidermal cells. Br J Dermatol. Apr 1994;130(4):424‐431. doi:10.1111/j.1365-2133.1994.tb03373.x

44.

Dam

Moller

Hindkjaer

Kragballe

. The vitamin D3 analog calcipotriol suppresses the number and antigen-presenting function of Langerhans cells in normal human skin. J Investig Dermatol Symp Proc. Apr 1996;1(1):72‐77.

45.

Karthaus

van Spriel

Looman

MWG

, et al. Vitamin D controls murine and human plasmacytoid dendritic cell function. J Invest Dermatol. May 2014;134(5):1255‐1264. doi:10.1038/jid.2013.501

46.

Fujiyama

Ito

Umayahara

, et al. Topical application of a vitamin D3 analogue and corticosteroid to psoriasis plaques decreases skin infiltration of TH17 cells and their ex vivo expansion. J Allergy Clin Immunol. Aug 2016;138(2):517‐528.e5. doi:10.1016/j.jaci.2016.03.048

47.

Disphanurat

Viarasilpa

Chakkavittumrong

Pongcharoen

. The clinical effect of oral vitamin D2 supplementation on psoriasis: A double-blind, randomized, placebo-controlled study. Dermatol Res Pract. 2019;2019:5237642. doi:10.1155/2019/5237642

48.

Ingram

Jones

Stonehouse

, et al. Oral vitamin D3 supplementation for chronic plaque psoriasis: A randomized, double-blind, placebo-controlled trial. J Dermatol Treat. 2018;29(7):648‐657. doi:10.1080/09546634.2018.1444728

49.

Kamiya

Kishimoto

Sugai

Komine

Ohtsuki

. Risk factors for the development of psoriasis. Int J Mol Sci. Sep 5 2019;20(18):4347. doi:10.3390/ijms20184347

50.

Reichrath

Saternus

Vogt

. Challenge and perspective: The relevance of ultraviolet (UV) radiation and the vitamin D endocrine system (VDES) for psoriasis and other inflammatory skin diseases. Photochem Photobiol Sci. Mar 16 2017;16(3):433‐444. doi:10.1039/c6pp00280c

51.

Barrea

Savanelli

Di Somma

, et al. Vitamin D and its role in psoriasis: An overview of the dermatologist and nutritionist. Rev Endocr Metab Disord. Jun 2017;18(2):195‐205. doi:10.1007/s11154-017-9411-6

Comparing Vitamin D Level Between Patients with Psoriasis and Healthy Individuals: A Systematic Review and Meta-Analysis

Abstract

Background

Methods

Results

Conclusion

Keywords

Introduction

Materials and Methods

Inclusion and Exclusion Criteria

Search Strategy

Study Selection

Data Extraction

Risk of Bias Assessment

Statistical Analysis

Results

Discussion

Conclusion

Footnotes

Declaration of Conflicting Interests

Funding

Author Contributions

ORCID iD

References